Literature DB >> 10760375

Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions.

T Rubino1, D Vigano', P Massi, M Spinello, E Zagato, G Giagnoni, D Parolaro.   

Abstract

When Delta(9)-tetrahydrocannabinol (Delta(9)-THC,15 mg/kg) was injected intraperitoneally twice a day for 6 days, tolerance to its analgesic effect appeared to be complete. Chronic exposure to Delta(9)-THC caused a significant reduction in CB1 receptor binding in all brain areas that contain this receptor. Cannabinoid receptor density was markedly reduced in the cerebellum (52%), hippocampus (40%) and globus pallidum (47%) compared to 30% in the cortex and striatum. Chronic exposure enhanced the cAMP pathway, as shown by the significant increase of cAMP levels and PKA activity in the areas with receptor down-regulation (cerebellum, striatum and cortex). We propose that the increase in cAMP cascade is part of the biochemical basis of cannabinoid tolerance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760375     DOI: 10.1016/s0028-3908(99)00196-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  21 in total

1.  Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats.

Authors:  Lina Yao; Krista McFarland; Peidong Fan; Zhan Jiang; Takashi Ueda; Ivan Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-09       Impact factor: 11.205

2.  Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.

Authors:  Diana L McKinney; Michael P Cassidy; Lauren M Collier; Billy R Martin; Jenny L Wiley; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2007-10-29       Impact factor: 4.030

Review 3.  Protein kinases and addiction.

Authors:  Anna M Lee; Robert O Messing
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

4.  CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Authors:  Liting Deng; Benjamin L Cornett; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

5.  Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling.

Authors:  Christine Börner; Michal Smida; Volker Höllt; Burkhart Schraven; Jürgen Kraus
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 6.  Marijuana dependence: not just smoke and mirrors.

Authors:  Divya Ramesh; Joel E Schlosburg; Jason M Wiebelhaus; Aron H Lichtman
Journal:  ILAR J       Date:  2011

Review 7.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

8.  Chronic administration during early adulthood does not alter the hormonally-dependent disruptive effects of delta-9-tetrahydrocannabinol (Δ9-THC) on complex behavior in female rats.

Authors:  Peter J Winsauer; Jessie L Sutton
Journal:  Pharmacol Biochem Behav       Date:  2013-12-18       Impact factor: 3.533

9.  Δ(9)Tetrahydrocannabinol impairs reversal learning but not extra-dimensional shifts in rhesus macaques.

Authors:  M J Wright; S A Vandewater; L H Parsons; M A Taffe
Journal:  Neuroscience       Date:  2013-01-16       Impact factor: 3.590

10.  Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells.

Authors:  Christopher Lipina; Clare Stretton; Simon Hastings; Jonathan S Hundal; Ken Mackie; Andrew J Irving; Harinder S Hundal
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.